Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance

Clin Imaging. 2015 May-Jun;39(3):454-62. doi: 10.1016/j.clinimag.2014.12.016. Epub 2015 Jan 8.

Abstract

Purpose: To compare various computed tomography (CT) parameters to the positron emission tomography with computed tomography (PET-CT) response, with or without PET guidance for the response assessment of colorectal cancer (CRC) metastases treated by Y90 radioembolization.

Methods: Thirty-six CRC metastases were retrospectively evaluated on 18F-Fluoro-Deoxy-Glucose PET-CT and contrast-enhanced computed tomography (CECT) performed at baseline and 2-3 months after Y90 radioembolization.

Results: Median SUVmax values decreased from 11.39 to 6.71 after radioembolization (P<.001), and 23/36 (64%) metastases were categorized metabolic responses according to European Organisation for Research and Treatment of Cancer criteria. Only a decrease of the mean attenuation in the structural (P<.001) and metabolic active volume (P<.001) was observed. The change in these criteria was correlated with the change of SUVmax.

Keywords: Colorectal cancer; Liver metastases; PET-CT; Radioembolization; Yttrium-90.

MeSH terms

  • Brachytherapy / methods
  • Colorectal Neoplasms / pathology*
  • Contrast Media*
  • Female
  • Fluorodeoxyglucose F18
  • Follow-Up Studies
  • Humans
  • Liver / diagnostic imaging
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / radiotherapy*
  • Liver Neoplasms / secondary*
  • Male
  • Middle Aged
  • Multimodal Imaging
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals
  • Retrospective Studies
  • Tomography, X-Ray Computed / methods*
  • Treatment Outcome
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Contrast Media
  • Radiopharmaceuticals
  • Yttrium Radioisotopes
  • Fluorodeoxyglucose F18